HeartBeam (Nasdaq:BEAT) announced today that it made significant developments in the AI applied to its proprietary ECG technology. Santa Clara, California-based HeartBeam develops its proprietary vectorelectrocardiography (VECG) technology. The company aims to provide diagnostic and prognostic insights about cardiac health beyond what standard 12-lead ECGs provide. HeartBeam’s VECG technology collects 3D signals of the heart […]
HeartBeam
HeartBeam names Deborah Castillo VP of regulatory affairs
HeartBeam (Nasdaq:BEAT) announced today that it appointed Deborah Castillo as its VP of regulatory affairs. Castillo, an experienced biomedical engineer, brings with her knowledge of the FDA, EU and Health Canada regulations, HeartBeam says. Her experience spans cardiovascular diseases, neuroscience and medical devices that support these functions. Before joining HeartBeam, Castillo served as director of […]
HeartBeam adds duo of medtech veterans to its board
HeartBeam (Nasdaq:BEAT) announced today that it appointed Ken Nelson and Mark Strome to its board of directors. The appointment of Nelson and Strome became effective on June 5, 2023. HeartBeam develops a proprietary 3D-vector ECG platform intended for patient use at home. Nelson, 48, brings with him 20 years of experience in digital health, medical […]
HeartBeam partners with Samsung to boost at-home cardiac care
HeartBeam has announced a strategic alliance agreement (SAA) with global tech giant Samsung. The alliance, announced today, builds upon an existing SAA between Samsung and Livmor, whose assets HeartBeam acquired earlier this year. Livmor created the FDA-cleared wearable Halo atrial fibrillation detection system — an FDA-cleared, Samsung-Galaxy-watch-based arrhythmia detection tool. Meanwhile, HeartBeam recently secured a […]
HeartBeam wins AI-related patent for handheld vector ECG
HeartBeam (Nasaq:BEAT) announced today that it received a key patent relating to AI capabilities for its AIMIGo system. The U.S. Patent and Trademark Office (USPTO) issued the allowance for a patent titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.” The patent describes a system that combines recorded cardiac signals from AIMIGo with […]
HeartBeam submits AIMIGo vector ECG for FDA 510(k) clearance
HeartBeam (Nasdaq:BEAT) announced today that it submitted a 510(k) application to the FDA for its AIMIGo system. AIMIGo, a personal, portable vector electrocardiogram (VECG) system assists patients and clinicians in assessing cardiac symptoms. It utilizes a reusable, credit card-sized VECG recording device and cloud-based software. The system can deliver critical data to clinicians in real-time outside […]
HeartBeam raises $23.2M
HeartBeam (Nasdaq:BEAT) announced on Wednesday that it closed a secondary offering of common stock worth $23.2 million. Santa Clara, California-based HeartBeam offered more than 16.6 million shares of its common stock. The offering amounts to net proceeds of $23.2 million after deducting placement agent discounts, commissions and offering expenses. Public Ventures LLC acted as placement […]
HeartBeam acquires patient monitoring assets from Livmor
HeartBeam (Nasdaq:BEAT) announced today that it acquired substantially all assets from Livmor, which develops remote monitoring technology. Livmor, a digital health solutions company, provides a patient-engaging remote monitoring system for critical physiological biomarkers. HeartBeam said in a news release that the acquisition extends its reach in remote monitoring and detection. It now has full ownership […]
HeartBeam appoints new president
HeartBeam (Nasdaq:BEAT) announced today that it appointed Robert Eno to its newly created position of president. Eno’s responsibilities include the company’s strategic direction, commercialization efforts and day-to-day operations. His role includes these responsibilities over the HeartBeam AIMI and HeartBeam AIMIGo platforms. The Santa Clara, California-based company designed AIMIGo as a credit card-sized, 12-lead 3D vector […]
HeartBeam expects FDA to approve AIMI system for acute care settings in 2023
In a letter to shareholders, HeartBeam (Nasdaq:BEAT) founder and CEO Branislav Vajdic laid out potential regulatory timelines for 2023. Calling 2022 “a transformative year,” Vajdic updated the expectations for HeartBeam’s AIMIGo and AIMI systems. The company designed AIMIGo as a credit card-sized, 12-lead 3D vector electrocardiogram (ECG) device. It developed AIMI for acute care settings. […]
HeartBeam names new chief medical officer
HeartBeam (Nasdaq:BEAT) announced today that it appointed Dr. Peter Fitzgerald as its new chief medical officer (CMO). Santa Clara, California–based HeartBeam develops a 3D-vector electrocardiogram (ECG) platform for heart attack detection. The company said in a news release that Fitzgerald joins with “world-renowned” expertise in interventional cardiology. HeartBeam also referred to him as an “accomplished […]